Esco Lifesciences supplies enabling technologies, products and services to the life sciences and healthcare industries, supporting academic research, clinical practice, and biopharmaceutical R&D and manufacturing. The company operates an extensive sales network in over 100 countries and maintains direct sales and service offices in more than 20 countries. It runs eight manufacturing and R&D hubs across the US, Europe, the UK, China and Singapore, and has over 1,300 employees worldwide. Esco plans to use the new funding to create an innovation hub in Boston focused on cell and gene therapy tools and technologies. Management intends to increase R&D and in-licensing efforts to develop and commercialize novel life-science research tools in emerging domains. The company is led by Chairman and CEO XQ Lin.

Total raised

$200M

Funding rounds

1

Latest round

Series A

Latest activity

May 2021